Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21416177 | 1.00 | HTT (0.51) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL11599076 | 0.85 | LMNA (0.49) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL11599079 | 0.85 | LMNA (0.49) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL2065470 | 0.84 | SMN1; SMN2 (0.59) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL10081124 | 0.84 | LMNA (0.63) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL7940762 | 0.83 | TGM2 (0.54) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL3231538 | 0.81 | PPID (0.64) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL10641387 | 0.79 | LMNA (0.61) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL16553601 | 0.79 | HTT (0.62) | HTTLMNASMN1; SMN2ALDH1A1TGM2 | |
| SCHEMBL11437278 | 0.79 | ALDH1A1 (0.56) | HTTLMNASMN1; SMN2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | HTT 4052/4885LMNA 2327/4885SMN1; SMN2 4187/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | HTT 4095/4885LMNA 2256/4885SMN1; SMN2 4162/4885 |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | HTT 4095/4885LMNA 2256/4885SMN1; SMN2 4162/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | HTT 4095/4885LMNA 2256/4885SMN1; SMN2 4162/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | HTT 4095/4885LMNA 2256/4885SMN1; SMN2 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.